AstraZeneca, Merck Get Europe OK for Two New Lynparza Indications
November 05 2020 - 10:36AM
Dow Jones News
By Colin Kellaher
AstraZeneca PLC and Merck & Co. on Thursday said the
European Commission approved two additional indications for their
cancer drug Lynparza.
The drugmakers said Lynparza is now approved as monotherapy for
the treatment of adults with metastatic castration-resistant
prostate cancer and BRCA1/2 mutations who have progressed following
a prior therapy that included a new hormonal agent.
The European Commission also approved the drug as a first-line
maintenance treatment in combination with bevacizumab for
HRD-positive advanced ovarian cancer.
AstraZeneca and Merck in 2017 formed a collaboration to
co-develop and co-commercialize Lynparza for multiple cancer
types.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 05, 2020 10:21 ET (15:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
